Table 1 Baseline demographic and clinical characteristics

From: A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer

Variable No. of patients (%)
Age (median year, range) 58 (28–75)
Gender
Male 54 (73.9)
Female 19 (26.0)
Tumour location
Upper body 10 (13.6)
Middle body 25 (34.2)
Lower body 36 (49.3)
Diffuse type 2 (2.7)
Tumour differentiation
Well/median differentiated 4 (5.4)
Poorly differentiated/mucinous or signet ring cell carcinoma 69 (94.5)
Pre-chemotherapy T stage
T2 9 (12.3)
T3 42 (57.5)
T4 22 (30.1)
Pre-chemotherapy N stage
N− 22 (30.1)
N+ 51 (69.9)
Pre-chemotherapy TNM
IB 5 (6.8)
II 49 (67.1)
III 19 (26.0)